Macroglossia: A potentially severe complication of late-onset Pompe disease.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
07 2022
Historique:
revised: 10 02 2022
received: 11 11 2021
accepted: 03 03 2022
pubmed: 19 3 2022
medline: 15 6 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

Pompe disease is a rare neuromuscular disorder caused by a deficiency of a lysosomal enzyme, acid α-glucosidase. Macroglossia is a classic clinical sign of several inherited myopathies and has also been reported to occur progressively in late-onset Pompe disease (LOPD). We describe patients with LOPD and macroglossia included in the French national Pompe disease registry. Clinical, functional, and radiological data were collected during periodic follow-up and analyzed retrospectively. These cases were compared with 15 previously reported cases. Five patients, three females and two males, aged 71-88 years, were included in this study. All but one of the patients suffered from symptoms related to macroglossia before the diagnosis of Pompe disease. Three had localized tongue atrophy and one had significant localized tongue hypertrophy which led to glossectomy 10 years before diagnosis. Two patients had severe dysphagia, one of whom underwent gastrostomy for enteral nutritional support. One patient experienced the persistence of numerous sleep apneas despite nocturnal bilevel positive airway pressure (BiPAP) ventilation. All our patients had dysarthria, and two required speech therapy. Four patients had a tongue hypersignal on magnetic resonance imaging (MRI) T1 sequences. Detection of macroglossia should be part of the clinical diagnosis and follow-up of patients with LOPD, with a careful evaluation of its main consequences. Macroglossia can have severe functional impacts on speech, swallowing, and sleep. Whole-body MRI with facial sections may facilitate the early diagnosis of Pompe disease with the "bright tongue sign".

Sections du résumé

BACKGROUND
Pompe disease is a rare neuromuscular disorder caused by a deficiency of a lysosomal enzyme, acid α-glucosidase. Macroglossia is a classic clinical sign of several inherited myopathies and has also been reported to occur progressively in late-onset Pompe disease (LOPD).
METHODS
We describe patients with LOPD and macroglossia included in the French national Pompe disease registry. Clinical, functional, and radiological data were collected during periodic follow-up and analyzed retrospectively. These cases were compared with 15 previously reported cases.
RESULTS
Five patients, three females and two males, aged 71-88 years, were included in this study. All but one of the patients suffered from symptoms related to macroglossia before the diagnosis of Pompe disease. Three had localized tongue atrophy and one had significant localized tongue hypertrophy which led to glossectomy 10 years before diagnosis. Two patients had severe dysphagia, one of whom underwent gastrostomy for enteral nutritional support. One patient experienced the persistence of numerous sleep apneas despite nocturnal bilevel positive airway pressure (BiPAP) ventilation. All our patients had dysarthria, and two required speech therapy. Four patients had a tongue hypersignal on magnetic resonance imaging (MRI) T1 sequences.
CONCLUSIONS
Detection of macroglossia should be part of the clinical diagnosis and follow-up of patients with LOPD, with a careful evaluation of its main consequences. Macroglossia can have severe functional impacts on speech, swallowing, and sleep. Whole-body MRI with facial sections may facilitate the early diagnosis of Pompe disease with the "bright tongue sign".

Identifiants

pubmed: 35302691
doi: 10.1111/ene.15330
doi:

Substances chimiques

alpha-Glucosidases EC 3.2.1.20

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2121-2128

Informations de copyright

© 2022 European Academy of Neurology.

Références

Pompe JC. Over idiopathische hypertrophie van het hart. Ned Tijdschr Geneeskd. 1932;76:304-311.
van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. 2008;372(9646):1342-1353.
Lefeuvre C, Clément G, Azzedine A, et al. Registre français de la maladie de Pompe : une cohorte de 210 patients adultes. Rev Neurol. 2021;1:S78.
Engel AG, Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain. 1970;93(3):599-616.
Laforêt P, Nicolino M, Eymard PB, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55(8):1122-1128.
Meola G, Scarpini E, Manfredi L, et al. Infantile-acute acid maltase deficiency (Pompe’s disease): studies of muscle cultures. Basic Appl Histochem. 1984;28(3):245-55.
Hudgson P, Gardner-Medwin D, Worsfold M, Pennington RJ, Walton JN. Adult myopathy from glycogen storage disease due to acid maltase deficiency. Brain J Neurol. 1968;91(3):435-462.
van der Walt JD, Swash M, Leake J, Cox EL. The pattern of involvement of adult-onset acid maltase deficiency at autopsy. Muscle Nerve. 1987;10(3):272-281.
Winkel LPF, Hagemans MLC, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252(8):875-884.
Benz K, Hahn P, Hanisch M, Lücke K, Lücke T, Jackowski J. Systematic review of oral and craniofacial findings in patients with Fabry disease or Pompe disease. Br J Oral Maxillofac Surg. 2019;57(9):831-838.
Jones HN, Hobson-Webb LD, Kuchibhatla M, et al. Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy. Mol Genet Metab. 2021;133(3):261-268.
Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation: lingual weakness in Pompe. Muscle Nerve. 2011;44(6):897-901.
Jones HN, Crisp KD, Asrani P, Sloane R, Kishnani PS. Quantitative assessment of lingual strength in late-onset Pompe disease: lingual strength in LOPD. Muscle Nerve. 2015;51(5):731-735.
Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: report of affected sibs and review of the literature. Medicine. 1995;74(3):131-135.
Barnes D, Hughes RA, Spencer GT. Adult-onset acid maltase deficiency with prominent bulbar involvement and ptosis. J R Soc Med. 1993;86(1):50.
Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord. 2013;23(4):319-323.
Margolis ML, Howlett P, Goldberg R, Eftychiadis A, Levine S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest. 1994;105(3):947-949.
Milisenda JC, Pujol T, Grau JM. Not only bright tongue sign in Pompe disease. Neurology. 2016;87(15):1629-1630.
de Pinto WBVR, Souza PVS, Bortholin T, Naylor FGM, Oliveira ASB. Abnormal tongue features as a clinical clue for late-onset Pompe’s disease. Arq Neuropsiquiatr. 2017;75(11):835-836.
Karam C, Dimitrova D, Yutan E, Chahin N. Bright tongue sign in patients with late-onset Pompe disease. J Neurol. 2019;266(10):2518-2523.
Carlier R-Y, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns [Internet]. Neuromuscular disorders : NMD. Neuromuscul Disord. 2011;21: 791-799.

Auteurs

Charlotte Dupé (C)

Neurology Department, APHP, Raymond Poincaré University Hospital, Garches, France.

Claire Lefeuvre (C)

Neurology Department, APHP, Raymond Poincaré University Hospital, Garches, France.
U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.

Guilhem Solé (G)

Neuromuscular Reference Center, Bordeaux University Hospital (Pellegrin), University of Bordeaux, Bordeaux, France.

Anthony Behin (A)

Institute of Myology, Pitié Salpêtrière Hospital, Paris, France.

Corinne Pottier (C)

Neurology Department, René Dubos Hospital, Pontoise, France.

Fanny Duval (F)

Neuromuscular Reference Center, Bordeaux University Hospital (Pellegrin), University of Bordeaux, Bordeaux, France.

Robert-Yves Carlier (RY)

U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.
Diagnostic and Interventional Medical Imaging Department, Raymond Poincaré Hospital, Garches, APHP, DMU Smart Imaging, GH Université Paris-Saclay, Garches, France.
Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, Garches, France.

Hélène Prigent (H)

U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.
Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, Garches, France.
Physiology Department, APHP, Raymond Poincaré University Hospital, Garches, France.

Jean Lacau St Guily (J)

Otolaryngology Head Neck Surgery Department, Rothschild Foundation Hospital and Sorbonne University, Paris, France.

Azzeddine Arrassi (A)

Neurology Department, René Dubos Hospital, Pontoise, France.
Diagnostic and Interventional Medical Imaging Department, Raymond Poincaré Hospital, Garches, APHP, DMU Smart Imaging, GH Université Paris-Saclay, Garches, France.

Nadjib Taouagh (N)

Institute of Myology, Pitié Salpêtrière Hospital, Paris, France.
Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, Garches, France.

Dalil Hamroun (D)

CHRU de Montpellier, Direction de la Recherche et de l'Innovation, Hôpital La Colombière, Montpellier, France.

Guillaume Nicolas (G)

Neurology Department, APHP, Raymond Poincaré University Hospital, Garches, France.
U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.

Pascal Laforêt (P)

Neurology Department, APHP, Raymond Poincaré University Hospital, Garches, France.
U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH